Exploring Innovative Leishmaniasis Treatment: Drug Targets from Pre-Clinical to Clinical Findings.
clinical
drug repurposing
leishmaniasis
new targets
pre-clinical
Journal
Chemistry & biodiversity
ISSN: 1612-1880
Titre abrégé: Chem Biodivers
Pays: Switzerland
ID NLM: 101197449
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
27
04
2021
accepted:
13
07
2021
pubmed:
10
8
2021
medline:
6
11
2021
entrez:
9
8
2021
Statut:
ppublish
Résumé
Leishmaniasis is a group of tropical diseases caused by parasitic protozoa belonging to the genus Leishmania. The disease is categorized in cutaneous leishmaniasis (CL), mucocutaneous leishmaniasis (MCL), and visceral leishmaniasis (VL). The conventional treatment is complex and can present high toxicity and therapeutic failures. Thus, there is a continuing need to develop new treatments. In this review, we focus on the novel molecules described in the literature with potential leishmanicidal activity, categorizing them in pre-clinical (in vitro, in vivo), drug repurposing and clinical research.
Identifiants
pubmed: 34369662
doi: 10.1002/cbdv.202100336
doi:
Substances chimiques
Antiprotozoal Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2100336Subventions
Organisme : Conselho Nacional de Desenvolvimento Científico e Tecnológico
ID : 301964/2019-0
Organisme : Conselho Nacional de Desenvolvimento Científico e Tecnológico
ID : No. 06/2019
Organisme : Conselho Nacional de Desenvolvimento Científico e Tecnológico
ID : No. 01/2019
Organisme : Portuguese Science and Technology Foundation
Organisme : Ministry of Science and Education
ID : M-ERA-NET-0004/2015-PAIRED
Informations de copyright
© 2021 Wiley-VHCA AG, Zurich, Switzerland.
Références
S. S. Oliveira, C. S. Ferreira, M. H. Branquinha, A. L. Santos, M. V. Chaud, S. Jain, J. C. Cardoso, A. B. Kovačević, E. B. Souto, P. Severino, ‘Overcoming multi-resistant leishmania treatment by nanoencapsulation of potent antimicrobials’, J. Chem. Technol. Biotechnol. 2021, 96, 2123-2140.
H. Akuffo, C. Costa, J. van Griensven, S. Burza, J. Moreno, M. Herrero, ‘New insights into leishmaniasis in the immunosuppressed’, PLoS Neglected Trop. Dis. 2018, 12, e0006375.
E. B. Souto, J. Dias-Ferreira, S. A. Craveiro, P. Severino, E. Sanchez-Lopez, M. L. Garcia, A. M. Silva, S. B. Souto, S. Mahant, ‘Therapeutic Interventions for Countering Leishmaniasis and Chagas's Disease: From Traditional Sources to Nanotechnological Systems’, Pathogenesis 2019, 8.
N. E. Aronson, ‘Addressing a clinical challenge: Guidelines for the diagnosis and treatment of leishmaniasis’, BMC Med. 2017, 15, 1-3.
E. Torres-Guerrero, M. R. Quintanilla-Cedillo, J. Ruiz-Esmenjaud, R. Arenas, ‘Leishmaniasis: a review’, F1000Research 2017, 6.
N. Varma, S. Naseem, ‘Hematologic changes in visceral leishmaniasis/kala azar’, Ind. J. Hem. Blood Transf. 2010, 26, 78-82.
WHO, Vol. 2021, https://www.who.int/en/news-room/fact-sheets/detail/leishmaniasis, 2020.
A. Akhlagh, A. Salehzadeh, A. H. Zahirnia, B. Davari, ‘10-year trends in epidemiology, diagnosis, and treatment of cutaneous Leishmaniasis in Hamadan Province, West of Iran (2007-2016)’, Frontiers Pub. Health 2019, 7, 27.
J. Sunter, K. Gull, ‘Shape, form, function and Leishmania pathogenicity: from textbook descriptions to biological understanding’, Open Biol. 2017, 7, 170165.
P. A. Bates, ‘Transmission of Leishmania metacyclic promastigotes by phlebotomine sand flies’, Int. J. Parasitol. 2007, 37, 1097-1106.
A. Dostálová, P. Volf, ‘Leishmania development in sand flies: parasite-vector interactions overview’, Parasites & Vectors 2012, 5, 1-12.
B. S. Mcgwire, A. Satoskar, ‘Leishmaniasis: clinical syndromes and treatment’, Q. J. Med. 2014, 107, 7-14.
S. Jain, W. Santana, S. S. Dolabella, A. L. S. Santos, E. B. Souto, P. Severino, ‘Are Nanobiosensors an Improved Solution for Diagnosis of Leishmania?’ Pharmaceutica 2021, 13, 491.
J. P. B. de Menezes, C. E. S. Guedes, A. L. d. O. A. Petersen, D. B. M. Fraga, P. S. T. Veras, ‘Advances in development of new treatment for leishmaniasis’, BioMed Res. Int. 2015, 2015. Article ID 815023.
S. Sundar, J. Chakravarty, D. Agarwal, M. Rai, H. W. Murray, ‘Single-dose liposomal amphotericin B for visceral leishmaniasis in India’, New Eng. J. Med. 2010, 362, 504-512.
N. M. Ikeogu, G. N. Akaluka, C. A. Edechi, E. S. Salako, C. Onyilagha, A. F. Barazandeh, J. E. Uzonna, ‘Leishmania immunity: advancing immunotherapy and vaccine development’, Microorganisms 2020, 8, 1201.
E. Diro, L. Lynen, K. Ritmeijer, M. Boelaert, A. Hailu, J. van Griensven, ‘Visceral leishmaniasis and HIV coinfection in East Africa’, PLoS Neglected Trop. Dis. 2014, 8, e2869.
J. Chakravarty, S. Sundar, ‘Drug resistance in leishmaniasis’, J. Global Infectious Diseases 2010, 2, 167.
N. Singh, M. Kumar, R. K. Singh, ‘Leishmaniasis: current status of available drugs and new potential drug targets’, Asian Pac. J. Trop. Dis. 2012, 5, 485-497.
S. Sundar, J. Chakravarty, ‘Leishmaniasis: an update of current pharmacotherapy’, Exp. Op. Pharmacother. 2013, 14, 53-63.
S. Burza, R. Mahajan, P. K. Sinha, J. van Griensven, K. Pandey, M. A. Lima, M. G. Sanz, T. Sunyoto, S. Kumar, G. Mitra, ‘Visceral leishmaniasis and HIV co-infection in Bihar, India: long-term effectiveness and treatment outcomes with liposomal amphotericin B (AmBisome)’, PLoS Neglected Trop. Dis. 2014, 8, e3053.
V. V. Andrade Neto, E. F. Cunha Junior, V. d. S. Faioes, T. P. Martins, R. L. Silva, L. L. Leon, E. C. T. Santos, ‘Leishmaniasis treatment: update of possibilities for drug repurposing’, Front. Biosci. 2018. 23, 967-996.
A. Ponte-Sucre, F. Gamarro, J.-C. Dujardin, M. P. Barrett, R. López-Vélez, R. García-Hernández, A. W. Pountain, R. Mwenechanya, B. Papadopoulou, ‘Drug resistance and treatment failure in leishmaniasis: A 21st century challenge’, PLoS Neglected Trop. Dis. 2017, 11, e0006052.
A. Cronemberger-Andrade, L. Aragao-Franca, C. F. de Araujo, V. J. Rocha, M. da Cruz Borges-Silva, C. P. Figueiras, P. R. Oliveira, L. A. de Freitas, P. S. Veras, L. Pontes de Carvalho, ‘Extracellular vesicles from Leishmania-infected macrophages confer an anti-infection cytokine-production profile to naive macrophages’, PLoS Neglected Trop. Dis. 2014, 8, e3161.
V. Stone, H. Johnston, R. P. Schins, ‘Development of in vitro systems for nanotoxicology: methodological considerations’, Crit. Rev. Toxicol. 2009, 39, 613-626.
V. V. G. de Oliveira, M. A. A. de Souza, R. R. M. Cavalcanti, M. V. de Oliveira Cardoso, A. C. L. Leite, V. A. da Silva Junior, R. C. B. Q. de Figueiredo, ‘Study of in vitro biological activity of thiazoles on Leishmania (Leishmania) infantum’, J. Glob. Antimicrob. Res. 2020, 22, 414-421.
I. S. Chauhan, G. S. Rao, J. Shankar, L. K. S. Chauhan, G. J. Kapadia, N. Singh, ‘Chemoprevention of Leishmaniasis: In-vitro antiparasitic activity of dibenzalacetone, a synthetic curcumin analog leads to apoptotic cell death in Leishmania donovani’, Parasitol. Int. 2018, 67, 627-636.
P. Chaubey, B. Mishra, S. L. Mudavath, R. R. Patel, S. Chaurasia, S. Sundar, V. Suvarna, M. Monteiro, ‘Mannose-conjugated curcumin-chitosan nanoparticles: Efficacy and toxicity assessments against Leishmania donovani’, Int. J. Biol. Macromol. 2018, 111, 109-120.
S. Asthana, A. K. Jaiswal, P. K. Gupta, V. K. Pawar, A. Dube, M. K. Chasia, ‘Immunoadjuvant chemotherapy of visceral leishmaniasis in hamsters using amphotericin B-encapsulated nanoemulsion template-based chitosan nanocapsules’, Antimicrob. Agents Chemother. 2013, 57, 1714-1722.
R. Salah-Tazdaït, D. Tazdaït, Z. Harrat, N. Eddaikra, F. Moulti-Mati, N. Abdi, N. Mameri, ‘Antileishmanial activity of low molecular weight chitin prepared from shrimp shell waste’, in: Multidisciplinary Approaches for Studying and Combating Microbial Pathogens, by A. Mendes-Vilas (Ed), BrownWalker Press, Boca Raton, USA, 2015, 39-43.
M. H. M. Hoseini, M. Moradi, M. H. Alimohammadian, V. K. Shahgoli, H. Darabi, A. Rostami, ‘Immunotherapeutic effects of chitin in comparison with chitosan against Leishmania major infection’, Parasitol. Int. 2016, 65, 99-104.
A. Riezk, K. Van Bocxlaer, V. Yardley, S. Murdan, S. L. Croft, ‘Activity of Amphotericin B-Loaded Chitosan Nanoparticles against Experimental Cutaneous Leishmaniasis’, Molecules 2020, 25, 4002.
R. El Hajj, Efficacité d'un analog d'Imiqualines, l'EAPB0503: Un nouveau traitement prometteur contre la Leishmaniose Cutanée, in Thèse de doctorat en Biologie Santé, cadre de Sciences Chimiques et Biologiques pour la Santé (Montpellier; Ecole Doctorale), en partenariat avec Institut des Biomolécules Max Mousseron (Montpellier), 2018.
C. S. F. Marques, N. S. Barreto, S. S. C. d. Oliveira, A. L. S. Santos, M. H. Branquinha, D. P. d. Sousa, M. Castro, L. N. Andrade, M. M. Pereira, C. F. d. Silva, M. V. Chaud, S. Jain, A. T. Fricks, E. B. Souto, P. Severino, ‘β-Cyclodextrin/Isopentyl Caffeate Inclusion Complex: Synthesis, Characterization and Antileishmanial Activity’, Molecules 2020, 25, 4181.
S. S. C. Oliveira, C. S. F. Marques, D. P. de Sousa, L. N. Andrade, A. T. Fricks, S. Jain, M. H. Branquinha, E. B. Souto, A. L. S. Santos, P. Severino, ‘Analysis of the mechanisms of action of isopentenyl caffeate against Leishmania’, Biochimie 2021, 189, 158-167.
J. Brindha, M. M. Balamurali, K. Chanda, ‘An Overview on the Therapeutics of Neglected Infectious Diseases-Leishmaniasis and Chagas Diseases’, Front. Chem. 2021, 9.
C. S. Freitas, D. P. Lage, J. A. Oliveira-da-Silva, R. R. Costa, D. V. C. Mendonça, V. T. Martins, T. A. R. Reis, L. M. R. Antinarelli, A. S. Machado, G. S. V. Tavares, F. F. Ramos, R. C. F. Brito, F. Ludolf, M. A. Chávez-Fumagalli, B. M. Roatt, G. S. Ramos, J. Munkert, F. M. Ottoni, P. R. V. Campana, M. C. Duarte, D. U. Gonçalves, E. S. Coimbra, F. C. Braga, R. M. Pádua, E. A. F. Coelho, ‘In vitro and in vivo antileishmanial activity of β-acetyl-digitoxin, a cardenolide of Digitalis lanata potentially useful to treat visceral leishmaniasis’, Parasite (Paris, France) 2021, 28, 38.
W. Huang, N. Percie du Sert, J. Vollert, A. S. C. Rice, ‘General Principles of Preclinical Study Design’, Hand. Exp. Pharmacol. 2020, 257, 55-69.
J. A. Cavagnaro, ‘Preclinical safety evaluation of biotechnology-derived pharmaceuticals’, Nat. Rev. Drug Discovery 2002, 1, 469-475.
P. Bilbao-Ramos, D. R. Serrano, H. K. Ruiz Saldaña, J. J. Torrado, F. Bolás-Fernández, M. A. Dea-Ayuela, ‘Evaluating the potential of ursolic acid as bioproduct for cutaneous and visceral leishmaniasis’, Molecules 2020, 25, 1394.
N. R. F. do Nascimento, F. L. N. de Aguiar, C. F. Santos, A. M. L. Costa, D. de Jesus Hardoim, K. da Silva Calabrese, F. Almeida-Souza, E. H. S. de Sousa, L. G. de França Lopes, M. J. Teixeira, ‘In vitro and in vivo leishmanicidal activity of a ruthenium nitrosyl complex against Leishmania (Viannia) braziliensis’, Acta Trop. 2019, 192, 61-65.
K. Horiuchi, S. Shiota, T. Hatano, T. Yoshida, T. Kuroda, T. Tsuchiya, ‘Antimicrobial activity of oleanolic acid from Salvia officinalis and related compounds on vancomycin-resistant enterococci (VRE)’, Biol. Pharm. Bull. 2007, 30, 1147-1149.
T. G. Soyer, D. V. Mendonça, G. S. Tavares, D. P. Lage, D. S. Dias, P. A. Ribeiro, L. Perin, F. Ludolf, V. T. Coelho, A. C. Ferreira, ‘Evaluation of the in vitro and in vivo antileishmanial activity of a chloroquinolin derivative against Leishmania species capable of causing tegumentary and visceral leishmaniasis’, Exp. Parasitol. 2019, 199, 30-37.
T. Marcusso Orsini, N. Y. Kawakami, C. Panis, A. P. Fortes dos Santos Thomazelli, F. Tomiotto-Pellissier, A. H. D. Cataneo, D. Kian, L. Megumi Yamauchi, F. S. Gouveia Júnior, L. G. de França Lopes, ‘Antileishmanial activity and inducible nitric oxide synthase activation by RuNO complex’, Med. Inflamm. 2016, 2016. Article ID 2631625.
L. Staurengo-Ferrari, S. S. Mizokami, J. J. Silva, F. O. da Silva, E. H. Sousa, L. G. da França, M. L. Matuoka, S. R. Georgetti, M. M. Baracat, R. Casagrande, ‘The ruthenium NO donor,[Ru (bpy) 2 (NO) SO3](PF6), inhibits inflammatory pain: involvement of TRPV1 and cGMP/PKG/ATP-sensitive potassium channel signaling pathway’, Pharmacol. Biochem. Behav. 2013, 105, 157-165.
M. W. S. Campelo, R. B. Oriá, L. G. de França Lopes, G. A. de Castro Brito, A. A. dos Santos, R. C. de Vasconcelos, F. O. N. da Silva, B. N. Nobrega, M. T. Bento-Silva, P. R. L. de Vasconcelos, ‘Preconditioning with a novel metallopharmaceutical NO donor in anesthetized rats subjected to brain ischemia/reperfusion’, Neurochem. Res. 2012, 37, 749-758.
E. H. Silva Sousa, L. A. Ridnour, F. n. S. Gouveia Jr, C. D. Silva da Silva, D. A. Wink, L. G. de França Lopes, P. J. Sadler, ‘Thiol-activated HNO release from a ruthenium antiangiogenesis complex and HIF-1α inhibition for cancer therapy’, ACS Chem. Biol. 2016, 11, 2057-2065.
J. J. N. Silva, P. M. M. Guedes, A. Zottis, T. L. Balliano, F. O. Nascimento Silva, L. G. França Lopes, J. Ellena, G. Oliva, A. D. Andricopulo, D. W. Franco, ‘Novel ruthenium complexes as potential drugs for Chagas's disease: enzyme inhibition and in vitro/in vivo trypanocidal activity’, Br. J. Pharmacol. 2010, 160, 260-269.
A. P. M. Santana, B. M. Tavares, L. T. Lucetti, F. S. Gouveia Jr, R. A. Ribeiro, P. M. Soares, E. H. Sousa, L. G. Lopes, J.-V. R. Medeiros, M. H. Souza, ‘The nitric oxide donor cis-[Ru (bpy) 2 (SO3) NO](PF6) increases gastric mucosa protection in mice-Involvement of the soluble guanylate cyclase/KATP pathway’, Nitric Oxide 2015, 45, 35-42.
J. C. M. Pereira, V. Carregaro, D. L. Costa, J. S. da Silva, F. Q. Cunha, D. W. Franco, ‘Antileishmanial activity of ruthenium (II) tetraammine nitrosyl complexes’, Eur. J. Med. Chem. 2010, 45, 4180-4187.
K. A. da Franca Rodrigues, D. K. F. Silva, V. de Lima Serafim, P. N. Andrade, A. F. Alves, W. L. Tafuri, T. M. Batista, V. M. Mangueira, M. V. Sobral, R. O. de Moura, ‘SB-83, a 2-Amino-thiophene derivative orally bioavailable candidate for the leishmaniasis treatment’, Biomed. Pharmacother. 2018, 108, 1670-1678.
A. E.-G. E. Amr, M. H. Sherif, M. G. Assy, M. A. Al-Omar, I. Ragab, ‘Antiarrhythmic, serotonin antagonist and antianxiety activities of novel substituted thiophene derivatives synthesized from 2-amino-4, 5, 6, 7-tetrahydro-N-phenylbenzo [b] thiophene-3-carboxamide’, Eur. J. Med. Chem. 2010, 45, 5935-5942.
E. Aguilera, C. Perdomo, A. Espindola, I. Corvo, P. Faral-Tello, C. Robello, E. Serna, F. Benítez, R. Riveros, S. Torres, ‘A Nature-Inspired Design Yields a New Class of Steroids Against Trypanosomatids’, Molecules 2019, 24, 3800.
M. Van den Kerkhof, D. Mabille, E. Chatelain, C. Mowbray, S. Braillard, S. Hendrickx, L. Maes, G. Caljon, ‘In vitro and in vivo pharmacodynamics of three novel antileishmanial lead series’, Int. J. Parasitol. 2018, 8, 81-86.
K. Van Bocxlaer, D. Caridha, C. Black, B. Vesely, S. Leed, R. J. Sciotti, G.-J. Wijnant, V. Yardley, S. Braillard, C. E. Mowbray, ‘Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis’, Int. J. Parasitol. 2019, 11, 129-138.
S. Wyllie, M. Thomas, S. Patterson, S. Crouch, M. De Rycker, R. Lowe, S. Gresham, M. D. Urbaniak, T. D. Otto, L. Stojanovski, ‘Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis’, Nature 2018, 560, 192-197.
A. Efstathiou, D. Smirlis, ‘Leishmania Protein Kinases: Important Regulators of the Parasite Life Cycle and Molecular Targets for Treating Leishmaniasis’, Microorganisms 2021, 9, 691.
S. Wyllie, S. Brand, M. Thomas, M. De Rycker, C.-W. Chung, I. Pena, R. P. Bingham, J. A. Bueren-Calabuig, J. Cantizani, D. Cebrian, ‘Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition’, Proc. Nat. Acad. Sci. 2019, 116, 9318-9323.
A. M. Thompson, A. Blaser, B. D. Palmer, R. F. Anderson, S. S. Shinde, D. Launay, E. Chatelain, L. Maes, S. G. Franzblau, B. Wan, ‘6-Nitro-2, 3-dihydroimidazo [2, 1-b][1, 3] thiazoles: Facile synthesis and comparative appraisal against tuberculosis and neglected tropical diseases’, Bioorg. Med. Chem. Lett. 2017, 27, 2583-2589.
W. G. Lima, M. C. Ramos-Alves, A. C. Soares, ‘Dos distúrbios psiquiátricos à antibioticoterapia: reposicionamento da clorpromazina como agente antibacteriano’, Rev. Colomb. Cienc. Quim.-Farm. 2019, 48, 5-28.
J. Fantini, C. Di Scala, H. Chahinian, N. Yahi, ‘Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection’, Int. J. Antimicrob. Agents 2020, 55, 105960.
G. Galindez, J. Matschinske, T. D. Rose, S. Sadegh, M. Salgado-Albarrán, J. Späth, J. Baumbach, J. K. Pauling, ‘Lessons from the COVID-19 pandemic for advancing computational drug repurposing strategies’, Nature Comp. Sci. 2021, 1, 33-41.
S. G. V. Rosa, W. C. Santos, ‘Clinical trials on drug repositioning for COVID-19 treatment’, Rev. Panam. Salud Publica 2020, 44, e40.
M. B. Serafin, A. Bottega, V. S. Foletto, T. F. d. Rosa, R. F. Rampelotto, F. A. Carvalho, R. Hörner, ‘Synergistic effect of sertraline and disulfiram against multidrug resistant bacteria as a new alternative to drug repositioning’, Braz. J. Pharm. Sci. 2020, 56.
J. H. da Silva Rodrigues, N. Miranda, H. Volpato, T. Ueda-Nakamura, C. V. Nakamura, ‘The antidepressant clomipramine induces programmed cell death in Leishmania amazonensis through a mitochondrial pathway’, Parasitol. Res. 2019, 118, 977-989.
M. El Mansari, P. Blier, ‘Mechanisms of action of current and potential pharmacotherapies of obsessive-compulsive disorder’, Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2006, 30, 362-373.
T. Benson, J. McKie, J. Garforth, A. Borges, A. Fairlamb, K. Douglas, ‘Rationally designed selective inhibitors of trypanothione reductase. Phenothiazines and related tricyclics as lead structures’, Biochem. J. 1992, 286, 9-11.
E. Bemani, A. Oryan, S. Bahrami, ‘Effectiveness of amiodarone in treatment of cutaneous leishmaniasis caused by Leishmania major’, Exp. Parasitol. 2019, 205, 107747.
M. Ágoston, F. Örsi, E. Fehér, K. Hagymási, Z. Orosz, A. Blázovics, J. Fehér, A. Vereckei, ‘Silymarin and vitamin E reduce amiodarone-induced lysosomal phospholipidosis in rats’, Toxicology 2003, 190, 231-241.
S. Cekic, D. Pavlovic, M. Sarac, B. Kamenov, A. Dimic, V. Pavlovic, ‘The effect of vitamin C on amiodarone-induced toxicity in rat thymocytes’, Open Med. Chem. J. 2011, 6, 58-63.
A. Jamshidzadeh, M. Baghban, N. Azarpira, A. M. Bardbori, H. Niknahad, ‘Effects of tomato extract on oxidative stress induced toxicity in different organs of rats’, Food Chem. Toxicol. 2008, 46, 3612-3615.
D. Punithavathi, N. Venkatesan, M. Babu, ‘Protective effects of curcumin against amiodarone-induced pulmonary fibrosis in rats’, Br. J. Pharmacol. 2003, 139, 1342-1350.
M. W. Roomi, N. W. Roomi, T. Kalinovsky, M. Rath, A. Niedzwiecki, ‘Prevention of amiodarone-induced cardiac toxicity in male BALB/c mice by a nutrient mixture’, Exp. Therap. Med. 2014, 7, 987-989.
E. de Morais-Teixeira, A. Rabello, M. M. G. Aguiar, ‘In vitro activity and in vivo efficacy of fexinidazole against New World Leishmania species’, J. Antimicrob. Chemother. 2019, 74, 2318-2325.
R. J. Soares-Bezerra, L. Leon, M. Genestra, ‘Recentes avanços da quimioterapia das leishmanioses: moléculas intracelulares como alvo de fármacos’, Rev. Bras. Cienc. Farm. 2004, 40, 139-149.
J. T. Bush, M. Wasunna, F. Alves, J. Alvar, P. L. Olliaro, M. Otieno, C. H. Sibley, N. S. Wourgaft, P. J. Guerin, ‘Systematic review of clinical trials assessing the therapeutic efficacy of visceral leishmaniasis treatments: A first step to assess the feasibility of establishing an individual patient data sharing platform’, PLoS Neglected Trop. Dis. 2017, 11, e0005781.
DNDi, https://dndi.org/research-development/portfolio/fexinidazole-vl, 2016.
S. Patterson, S. Wyllie, L. Stojanovski, M. R. Perry, F. R. Simeons, S. Norval, M. Osuna-Cabello, M. De Rycker, K. D. Read, A. H. Fairlamb, ‘The R enantiomer of the antitubercular drug PA-824 as a potential oral treatment for visceral leishmaniasis’, Antimicrob. Agents Chemother. 2013, 57, 4699-4706.
A. M. Thompson, P. D. O'Connor, A. J. Marshall, V. Yardley, L. Maes, S. Gupta, D. Launay, S. Braillard, E. Chatelain, B. Wan, ‘Heteroaryl ether analogs of an antileishmanial 7-substituted 2-nitroimidazooxazine lead afford attenuated hERG risk: In vitro and in vivo appraisal’, Eur. J. Med. Chem. 2021, 209, 112914.
G.-J. Wijnant, S. L. Croft, R. de la Flor, M. Alavijeh, V. Yardley, S. Braillard, C. Mowbray, K. Van Bocxlaer, ‘Pharmacokinetics and pharmacodynamics of the nitroimidazole DNDI-0690 in mouse models of cutaneous leishmaniasis’, Antimicrob. Agents Chemother. 2019, 63.
S. Wyllie, A. J. Roberts, S. Norval, S. Patterson, B. J. Foth, M. Berriman, K. D. Read, A. H. Fairlamb, ‘Activation of bicyclic nitro-drugs by a novel nitroreductase (NTR2) in Leishmania’, PLoS Pathog. 2016, 12, e1005971.
F. Alves, G. Bilbe, S. Blesson, V. Goyal, S. Monnerat, C. Mowbray, G. M. Ouattara, B. Pécoul, S. Rijal, J. Rode, ‘Recent development of visceral leishmaniasis treatments: successes, pitfalls, and perspectives’, Clin. Microbiol. Rev. 2018, 31.
DNDi, https://www.dndi.org/diseases-projects/portfolio/oxaborole-dndi-6148, 2018.
DNDi, https://www.isrctn.com/ISRCTN54981564, 2020.
A. Nagle, A. Biggart, C. Be, H. Srinivas, A. Hein, D. Caridha, R. J. Sciotti, B. Pybus, M. Kreishman-Deitrick, B. Bursulaya, ‘Discovery and characterization of clinical candidate LXE408 as a kinetoplastid-selective proteasome inhibitor for the treatment of leishmaniases’, J. Med. Chem. 2020, 63, 10773-10781.
NOVARTIS, Novartis and DNDi to collaborate on the development of a new oral drug to treat visceral leishmaniasis. Novartis and Drugs for Neglected Diseases initiative (DNDi). in, https://www.novartis.com/news/media-releases/novartis-and-dndi-collaborate-development-new-oral-drug-treat-visceral-leishmaniasis (accessed on: 7th January 2021).
E. A. Winzeler, S. Ottilie, ‘The proteasome as a target: How not tidying up can have toxic consequences for parasitic protozoa’, Proc. Nat. Acad. Sci. 2019, 116, 10198-10200.
GSK, Safety, Tolerability and Pharmacokinetics (PK) Investigation of GSK3494245 in Healthy Participants. GSK clinical trials, United Kingdom., in, https://ichgcp.net/clinical-trials-registry/NCT04504435 (accessed on: 7th January 2021).
R. El Hajj, H. Bou Youness, L. Lachaud, P. Bastien, C. Masquefa, P.-A. Bonnet, H. El Hajj, I. Khalifeh, ‘EAPB0503: An Imiquimod analog with potent in vitro activity against cutaneous leishmaniasis caused by Leishmania major and Leishmania tropica’, PLoS Neglected Trop. Dis. 2018, 12, e0006854.
A. Oryan, S. Bahrami, E. Bemani, ‘Efficacy of voriconazole on leishmaniasis by Leishmania major: An in vitro and in vivo study’, Asian Pac. J. Trop. Med. 2018, 11, 562.